| Author (year) |
Analytical Method |
Sample Source |
Subjects with bladder cancer(n) |
Controls (n) |
Up-regulated lipid metabolites |
Down-regulated lipid metabolites |
Ref |
| Dill et al. (2009) |
DESI-MS |
Tissue (canine) |
4 |
Adjacent normal bladder tissue (4) |
GlycerophosphocholinesLinoleic acid, Oleic acid Arachidonic acid |
Sphingomyelin |
[13] |
| Putluri et al. (2011) |
LC-MS |
Urine (human) Tissues(human) Bladder cancer (BC) cell lines |
83 |
Adjacent normal bladder tissue (51) |
Carnitine, Oleic acid Palmitic acid |
Lauric acid |
[20] |
| Cao et al. (2012) |
H-NMR |
Serum (human) |
LGBC (15) HGBC (22) |
Healthy subjects (25) Calculi patient (28) Post-TURBT patient (20) |
V/LDL Acetoacetate |
|
[16] |
| Lin et al. (2012) |
RPLC-MS HILIC- MS |
Serum (human) |
13 |
Healthy subjects (20) Nephrolit hiasis (8) BPH (10)
|
Phosphatidylcholine |
|
[12] |
| Zhang et al. (2012) |
H-NMR |
Urine (canine) |
Invasive BC (40) |
Healthy dogs (42) |
Choline, β hydroxybutyrate Acetone |
|
[17] |
| Pasikanti et al. (2013) |
GC×GC−TOFMS |
Urine (human) |
38 |
Non-BC subjects (61) |
|
Glycerol |
[15] |
| Triphati et al. (2013) |
HR-MAS NMR GC-MS |
Tissue (human) |
BC: Ta-T1(17) BC: ≥ T2 (16) |
Benign diseases (26) |
Phosphocholine, Choline Glycerophosphocholine |
Triglicerides |
[11] |
| Bansal et al. (2013) |
H-NMR |
Serum (human) |
LGBC (36) HGBC (31) |
Healthy subjects (32) |
Malonyl-CoA |
|
[14] |
| Jin et al. (2014) |
HPLC-QTOFMS |
Urine (human) |
NMIBC (83) MIBC (55) |
Healthy subjects (69) Hematuria due to non-malignant disease (5) |
Carnitine, Isovalerylcarnitine Octenoylcarnitine, Acetyl-CoA Carnitine palmitoyltransferase Carnitine acylcarnitine translocase like protein (CACL) |
Glutarylcarnitine Decanoylcarnitine |
[19] |
| Wittmann et al. (2015) |
UHPLC-MS/MS GC-MS |
Urine(human) |
Retrospective (cohort 1) |
Palmitoyl sphingomyelin Phosphocholine |
|
[9] |
| |
|
|
BC (66) |
Non-BC subjects (266) |
|
|
|
| |
|
|
Prospective (cohort 2) |
Arachidonate |
|
|
| |
|
|
BC (29) |
Non-BC subjects (79) |
|
|
|
DESI-MS: Desorption Electrospray İonization-Mass Spectrometry; LC-MS: Liquid Chromatography-Mass Spectrometry; BC: Bladder Cancer; H-NMR: H Nuclear Magnetic
Resonance; LGBC: Low Grade Bladder Cancer; HBC: High Grade Bladder Cancer; TURBT: Transurethral Resection of Bladder Tumor; RPLC-MS: Reversed Phase Liquid
Chromatography-Mass Spectrometry; HILIC-MS: Hydrophilic İnteraction Chromatography-Mass Spectrometry; BPH: Benign Prostate Hyperplasia; GC×GC−TOFMS: Gas
Chromatography Time of-Flight Mass Spectrometry; HR-MAS NMR: High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance; GC-MS: Gas Chromatography-
Mass Spectrometry; HPLC-QTOFMS: High-Performance Liquid Chromatography-Quadrupole Time-Of-Flight Mass Spectrometry; NMIBC: Non-Muscle Invasive Bladder
Cancer; UHPLC-MS/MS: Ultrahigh-Performance Liquid Chromatography/Tandem Mass Spectrometry